Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus lenvatinib vs TACE plus sorafenib for unresectable hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR2100046490Phase 4Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lenvatinib and sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Overall survival and Progression-free survival. Started Sep 2017; status: completed.
02
Drugs
lenvatinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100046490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046490.